| Literature DB >> 31441679 |
Ashraful Islam Khan1, Md Taufiqul Islam1, Shah Alam Siddique1, Shakil Ahmed1, Nurnabi Sheikh1, Ashraf Uddin Siddik1, Muhammad Shariful Islam1, Firdausi Qadri1.
Abstract
Background: The new influx of Forcibly Displaced Myanmar Nationals (FDMNs) into Bangladesh started in August 2017 through different entry points of Bangladesh. Considering the imminent threat of infectious diseases outbreaks, the Government of Bangladesh (GoB) decided to vaccinate children against three deadly diseases (measles, rubella and poliomyelitis) and oral cholera vaccine (OCV) for all except <1 year children. After completion of the campaigns, post-vaccination campaign evaluation was carried out to assess the coverage of OCV, OPV and MR vaccines during campaigns.Entities:
Keywords: Bangladesh; FDMN; MR; OCV; OPV; Vaccine; coverage
Mesh:
Substances:
Year: 2019 PMID: 31441679 PMCID: PMC6930105 DOI: 10.1080/21645515.2019.1616502
Source DB: PubMed Journal: Hum Vaccin Immunother ISSN: 2164-5515 Impact factor: 3.452
The vaccination period, target age group and population and the number of vaccinated participants by OPV, OCV and MR among FDMN.
| Vaccination campaigns | Date of campaign | Antigen & target age group | Target | No. of vaccinated participants | Remarks |
|---|---|---|---|---|---|
| bOPV, MR | 16 September–3 October 2017 | MR-6 Month to <15 years | 122,580 | 135,519 | New influx of FDMN started on 25 August 2017 |
| bOPV <5 years | 47,165 | 72,334 | |||
| OCV Campaign (1st Round) | 10–18 October 2017 | >1 year | 658,371 | 700,487 | |
| OCV and bOPV Campaign (2nd Round) | 4–9 November 2017 | bOPV- <5 years | 209,931 | 236,696 | |
| OCV-1 to <5 years | 182,317 | 199,472 |
Source: WHO country office.
Overall coverage rate of Rohingya vaccination coverage.
| Vaccination campaign | Target population (n) | Vaccinated population | Coverage rate (%) (95% CI) |
|---|---|---|---|
| 39438 | 36939 | 94 (93, 94) | |
| 7618 | 6984 | 92 (91, 92) | |
| 8959 | 6733 | 75 (74, 76) | |
| 8959 | 7926 | 88 (88, 89) | |
| 20288 | 7776 | 38 (38, 39) |
Association of vaccine coverage rate with the demographic characteristics.
| Variables | OCV1 | OCV2 | OPV1 | OPV2 | MR | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| AGE (years) | AOR (95% CI) | CR (%) | AOR (95% CI) | CR (%) | AOR (95% CI) | CR (%) | AOR (95% CI) | CR (%) | AOR (95% CI) | CR (%) |
| 1.07 (0.92, 1.54) | 95 | – | 92 | – | 75 | – | 88 | 1.12*(1.05, 1.27) | 41 | |
| 1.11(0.89, 1.59) | 95 | – | – | – | – | – | – | 1.00 | 36 | |
| 1.00 | 93 | – | – | – | – | – | – | – | – | |
| 1.09* (1.00, 1.18) | 94 | 0.98 (0.83, 1.16) | 92 | 1.03 (0.93, 1.13) | 75 | 0.99 (0.87, 1.14) | 88 | 1.07*(1.00, 1.13) | 39 | |
| 1.00 | 93 | 1.00 | 92 | 1.00 | 75 | 1.00 | 88 | 1.00 | 38 | |
| 1.04 (0.93, 1.59) | 93 | 0.99 (0.47, 1.19) | 91 | 0.41*(0.35, 0.48) | 71 | 0.98 (0.41, 1.63) | 87 | 0.66*(0.61, 0.71) | 35 | |
| 1.13*(1.04, 1.60) | 97 | 1.03 (0.91, 1.47) | 94 | 0.92 (0.71, 1.18) | 86 | 1.10 (0.93, 2.37) | 93 | 0.95 (0.84, 1.06) | 46 | |
| 1.00 | 91 | 1.00 | 91 | 1.00 | 87 | 1.00 | 88 | 1.00 | 47 | |
AOR: adjusted odds ratio; CR: coverage rate; *Significant (5% level).
Reasons for vaccine dose not taken.
| Reasons | OCV1 (%) | OCV2 (%) | OPV1 (%) | OPV2 (%) | MR (%) |
|---|---|---|---|---|---|
| 316 (12.65) | 129 (20.35) | 653 (29.34) | 215 (20.81) | 3841 (30.7) | |
| 258 (10.32) | 63 (9.94) | 206 (9.25) | 115 (11.13) | 1776 (14.19) | |
| 304 (12.16) | 93 (14.67) | 125 (5.62) | 119 (11.52) | 720 (5.75) | |
| 194 (7.76) | 86 (13.56) | 143 (6.42) | 122 (11.81) | 526 (4.2) | |
| 42 (1.68) | 27 (4.26) | 114 (5.12) | 19 (1.84) | 524 (4.19) | |
| 43 (1.72) | 24 (3.79) | 39 (1.75) | 33 (3.19) | 608 (4.86) | |
| 21 (0.84) | 5 (0.79) | 8 (0.36) | 16 (1.55) | 87 (0.70) | |
| 8 (0.32) | 2 (0.32) | 5 (0.22) | 6 (0.58) | 23 (0.18) | |
| 17 (0.68) | 3 (0.47) | 7 (0.31) | 3 (0.29) | 36 (0.29) | |
| 10 (0.40) | 0 (0.00) | 2 (0.09) | 1 (0.1) | 34 (0.27) | |
| 596 (23.85) | 89 (14.04) | 375 (16.85) | 119 (11.52) | 1508 (12.05) | |
| 690 (27.82) | 113 (17.82) | 549 (24.66) | 265 (25.65) | 2829 (22.61) | |